Participant Flow Module
The Participant Flow Module provides information about the flow of participants through each stage of the clinical trial. This includes pre-assignment details, recruitment information, and the types of units analyzed, helping researchers understand how participants move through the study.
Participant Flow Module path is as follows:
Study -> Results Section -> Participant Flow Module
Participant Flow Module
Ignite Creation Date:
2025-12-24 @ 9:08 PM
Ignite Modification Date:
2025-12-25 @ 6:59 PM
NCT ID:
NCT04182204
Pre Assignment Details:
The study was divided into 2 stages: Stage 1, or safety run-in (SRI), and Stage 2, or randomized controlled trial (RCT). Participants received polatuzumab vedotin in combination with rituximab + gemcitabine + oxaliplatin (Pola-R-GemOx) during the SRI stage. Participants were randomized in a 1:1 ratio to receive either Pola-R-GemOx or rituximab + gemcitabine + oxaliplatin (R-GemOx) in the RCT stage.
Recruitment Details:
A total of 270 participants with relapsed/refractory (r/r) diffuse large b-cell lymphoma (DLBCL) took part in the study at 64 investigative sites in 16 countries from 07 February 2020 to 29 November 2024.
Study:
NCT04182204
Study Brief:
Results Section:
NCT04182204